Summit Therapeutics Inc (SMMT) Stock Analysis
Verdict: WATCH (do not buy)
Ivonescimab's upcoming FDA decision offers major upside, but a $12.1B valuation and $168M quarterly burn require tight clinical execution.
Investment score: 45/100
Analysis as of
Is Summit Therapeutics Inc stock worth reviewing? AI model thesis
The AI model classifies Summit Therapeutics as a WATCH (Score: 45/100) due to its extreme valuation premium ($12.10B market cap on $0 TTM revenue) balanced against potent clinical momentum for bispecific antibody ivonescimab ahead of key FDA PDUFA milestones.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Summit Therapeutics Inc opportunities and risks
What speaks for SMMT
- Ivonescimab head-to-head Phase III superiority over Keytruda
What speaks against SMMT
- Regulatory rejection or delay due to reliance on single-region China data
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.4% |
| EXEL | 18.5x | 6.3x | 14.5x | 96.5% | 35.3% | 7.6% |
| NBIX | 19.3x | 4.1x | 15.1x | 98.0% | 20.9% | 6.3% |
| HALO | 33.2x | 8.0x | 21.2x | 82.4% | 24.9% | 6.1% |
| BBIO | n/a | 17.8x | n/a | 93.3% | -97.6% | -3.5% |
| BMRN | 145.1x | 3.1x | 36.3x | 75.5% | 2.1% | 6.9% |
| Peer median | 19.3x | 6.3x | 15.1x | 93.3% | 20.9% | 6.3% |
Frequently asked questions about Summit Therapeutics Inc (SMMT)
Is SMMT stock a good investment?
The cached TradeMates AI model rates Summit Therapeutics Inc as WATCH (do not buy) with an investment score of 45/100. The AI model classifies Summit Therapeutics as a WATCH (Score: 45/100) due to its extreme valuation premium ($12.10B market cap on $0 TTM revenue) balanced against potent clinical momentum for bispecific antibody ivonescimab ahead of key FDA PDUFA milestones. This is algorithmic model output, not personal investment advice.
Is SMMT stock a buy?
The TradeMates model verdict for SMMT is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.